Showing results (1671-1680 of 1,892) with videos related to

Sort By:
Pageof 190
Molecular Pharmaceutics|March 1, 2026
Attenuated Toxicity and Antitoxic Mechanism via Sodium Iodide Symporter Inhibition-Based Tumor-Selective Delivery in Astatine-211 RadioimmunotherapyHiroki Takashima, Ryo Tsumura, Yoshikatsu Koga, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 3, 2021
Neural correlates of beneficial effects of young plasma treatment in aged mice: PET-SPM analyses and neuro-behavioural/molecular biological studiesKai Zhang, Hiroshi Mizuma, Yuka Nakatani, et al.
Biological & Pharmaceutical Bulletin|March 1, 2022
Betulin Attenuates TGF-β1- and PGE2-Mediated Inhibition of NK Cell Activity to Suppress Tumor Progression and Metastasis in MiceMasaru Ogasawara, Shino Yamasaki-Yashiki, Masahiro Hamada, et al.
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|November 13, 2010
[A case of jejunal adenocarcinoma with serum DUPAN-2 elevation]Yuichi Yamaga, Masaya Ohana, Takefumi Nakamura, et al.
Biological & Pharmaceutical Bulletin|October 9, 2010
Association of the A-1438G polymorphism in serotonin 2A receptor in migraine with aura among Japanese patientsYuika Naito, Masakazu Ishii, Ayumu Nagamine, et al.
Psycho-Oncology|August 13, 2009
Feasibility and usefulness of the 'Distress Screening Program in Ambulatory Care' in clinical oncology practiceKen Shimizu, Yuki Ishibashi, Shino Umezawa, et al.
Viruses|December 23, 2023
Development of an Immunochromatography Assay to Detect Marburg Virus and Ravn VirusKatendi Changula, Masahiro Kajihara, Shino Muramatsu, et al.
ACS Omega|June 21, 2021
Stabilization of an 211At-Labeled Antibody with Sodium AscorbateShino Manabe, Hiroki Takashima, Kazunobu Ohnuki, et al.
The Journal of Biological Chemistry|May 16, 2018
Lipopolysaccharide (LPS)-binding protein stimulates CD14-dependent Toll-like receptor 4 internalization and LPS-induced TBK1-IKKϵ-IRF3 axis activationHiroki Tsukamoto, Shino Takeuchi, Kanae Kubota, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutationsHiroshi Tanaka, Miyuki Yoshida, Hiromi Tanimura, et al.
Pageof 190